



The Intensive Care Global Study 
on Severe Acute Respiratory Infection 
(IC-GLOSSARI): a multicenter, multinational, 
14-day inception cohort study
Yasser Sakr1*, Ricard Ferrer2, Konrad Reinhart1, Richard Beale3, Andrew Rhodes4, Rui Moreno5, 
Jean Francois Timsit6, Laurent Brochard7,8, B. Taylor Thompson9,10, Ederlon Rezende11 
and Jean Daniel Chiche12,13,14
© 2016 Springer-Verlag Berlin Heidelberg and ESICM 
Abstract 
Purpose: In this prospective, multicenter, 14-day inception cohort study, we investigated the epidemiology, patterns 
of infections, and outcome in patients admitted to the intensive care unit (ICU) as a result of severe acute respiratory 
infections (SARIs).
Methods: All patients admitted to one of 206 participating ICUs during two study weeks, one in November 2013 
and the other in January 2014, were screened. SARI was defined as possible, probable, or microbiologically confirmed 
respiratory tract infection with recent onset dyspnea and/or fever. The primary outcome parameter was in-hospital 
mortality within 60 days of admission to the ICU.
Results: Among the 5550 patients admitted during the study periods, 663 (11.9 %) had SARI. On admission to the 
ICU, Gram-positive and Gram-negative bacteria were found in 29.6 and 26.2 % of SARI patients but rarely atypical bac-
teria (1.0 %); viruses were present in 7.7 % of patients. Organ failure occurred in 74.7 % of patients in the ICU, mostly 
respiratory (53.8 %), cardiovascular (44.5 %), and renal (44.6 %). ICU and in-hospital mortality rates in patients with SARI 
were 20.2 and 27.2 %, respectively. In multivariable analysis, older age, greater severity scores at ICU admission, and 
hematologic malignancy or liver disease were independently associated with an increased risk of in-hospital death, 
whereas influenza vaccination prior to ICU admission and adequate antibiotic administration on ICU admission were 
associated with a lower risk.
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Take-home message: Admission to the ICU for SARI is common and 
associated with high morbidity and mortality rates. We identified several 
risk factors for in-hospital death that may be useful for risk stratification in 
these patients.
On behalf of the IC-GLOSSARI Investigators and the Trials Group of the 
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A complete list of IC-GLOSSARI investigators is provided in the “Appendix”.
Conclusions: Admission to the ICU for SARI is common and associated with high morbidity and mortality rates. We 
identified several risk factors for in-hospital death that may be useful for risk stratification in these patients.
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Introduction
Recent outbreaks of severe acute respiratory syndrome 
(SARS) and H1N1 influenza infection [1–4] have stimu-
lated an interest in the surveillance of patients with severe 
acute respiratory infection (SARI), defined by the World 
Health Organization as an acute respiratory illness of 
recent onset (within 7 days) that includes fever (≥38 °C), 
cough, and dyspnea requiring overnight hospitalization 
[5]. Whereas this definition of SARI may prove practi-
cal for surveillance systems, it provides little informa-
tion for intensive care physicians regarding the nature of 
infections, the spectrum of severity, or the diagnostic and 
treatment strategies used for the subset of these patients 
that ultimately requires intensive care unit (ICU) admis-
sion. Indeed, only a subset of the patients with SARI will 
require ICU admission for oxygen therapy or mechanical 
ventilation; a smaller subset will develop acute respira-
tory distress syndrome and sepsis and an even smaller 
proportion will require adjunctive treatments [6–8].
Obtaining accurate information on the epidemiology 
of critically ill patients with SARI and how these patients 
are currently diagnosed and treated should help inten-
sive care practitioners to understand the factors associ-
ated with progression from acute respiratory infection to 
more severe critical illness. Such information may also 
help identify high-risk populations and guide health-
care providers in resource allocation. It is also required 
to identify patients for future interventional studies and 
provide a framework to facilitate a rapid response of the 
ICU community to emerging epidemics.
We conducted a prospective, observational, inception 
cohort study to investigate the epidemiology and micro-
biological profiles of ICU-SARI, to document commonly 
used treatment and monitoring strategies, to measure 
current outcomes, and to identify risk factors for poor 
outcome in these patients.
Methods
The Intensive Care Global Study on Severe Acute Res-
piratory Infection (IC-GLOSSARI) study group was an 
initiative of the Trials Group of the European Society of 
Intensive Care Medicine (ESICM-TG). Participation was 
entirely voluntary, with no financial incentive. Institu-
tional review board approval was obtained by the partici-
pating institutions according to local ethical regulations. 
Informed consent was not required because of the obser-
vational and anonymous nature of the data collection. A 
steering committee was nominated by the ESICM-TG 
and was responsible for the scientific conduct and con-
sistency of the project. A list of contributing centers is 
provided in the “Appendix”.
Study design
The study was performed over 4  weeks, from 3 to 17 
November 2013 and from 13 to 26 January 2014. Each 
center included patients for two 1-week periods, one in 
November and the other in January. These dates were 
arbitrarily chosen to capture the expected peaks of 
admissions due to SARI. The same centers participated 
in both periods. All adult (≥18  years) patients admit-
ted to the participating ICUs during the study period 
(2  weeks per center) were screened. Patients admitted 
to the ICU due to SARI, defined as possible, probable, 
or microbiologically confirmed respiratory tract infec-
tion together with recent onset (within 7  days prior to 
ICU admission) dyspnea and/or fever (≥38  °C), were 
included in the study. Patients were excluded if they (1) 
were less than 18 years of age; (2) had had symptoms for 
more than 7 days; (3) were receiving invasive mechanical 
ventilation prior to admission for any reason other than 
general anesthesia for surgical procedures; and (4) had 
previously been included in the study during the same 
study period. As a result of the lack of data from simi-
lar studies on this specific population, it was not possible 
to estimate the sample size prior to inclusion. The study 
was purely observational and there was no study protocol 
for patient diagnosis or therapy. Patients were followed 
up for 60 days after admission to the ICU for in-hospital 
mortality.
Definitions
Infection was defined according to the definitions of the 
International Sepsis Forum (Table  E1) [9]. Organ fail-
ure was defined as a sequential organ failure assessment 
(SOFA) score  >2 for the organ in question. Hospital-
acquired SARI was defined as the development of SARI 
48 h or more after hospital admission [10]. The definition 
of healthcare-related infections is provided in Table  E1 
[10]. Patients were classified as having community-
acquired SARI if they did not fit the criteria for health-
care-related or hospital-acquired SARI.
Antibiotic therapy was considered adequate if the 
results of microbiology confirmed in  vitro sensitivity 
and/or if clinical improvement occurred with no need to 
change or escalate the antibiotic regimen within 7 days of 
the onset of therapy.
Data collection
Data were collected in individual centers on paper case 
record forms (CRFs) and were then transcribed by local 
investigators into a secure Internet-based platform. A 
minimal data set was recorded for all adult patients 
admitted to the participating ICUs during the two study 
weeks. This included the type of admission (surgical or 
not), use of mechanical ventilation on admission to the 
ICU and during the ICU stay, the ICU length of stay, and 
the ICU mortality. In patients with SARI, data collec-
tion on admission included demographic data, comorbid 
diseases, and the presenting signs and symptoms. Clini-
cal and laboratory data to calculate the SAPS  II score 
[11] were recorded as the worst values within 24 h after 
admission. Microbiologic and clinical infections were 
recorded daily as were the antibiotics administered. 
Organ function was evaluated daily using the SOFA score 
[12]. The daily data collection was performed for 28 days 
following admission to the ICU or until ICU discharge or 
death.
Data management and quality control
Detailed instructions were available for all participants 
before starting data collection and throughout the study 
period. Plausibility checks were performed for each vari-
able and between variables. Data were further reviewed 
by the primary investigator (YS) for plausibility and 
availability of outcome parameters, and any doubts were 
clarified with the center in question. Any file with more 
than 20 % missing data was excluded from the study. The 
reliability of data collection was further analyzed using 
Kappa statistics on a randomly selected 2  % of the col-
lected comorbidity and mortality data. Discordance was 
clarified through direct contact with the investigators 
and corrected in the final database. The Kappa coefficient 
ranged from 0.84 to 1.00 denoting very good agreement 
between collected data and the randomly recollected 
sample.
For single missing values of the SOFA score, the mean 
value of the results on either side of the absent result 
was imputed. When first or last values were missing, the 
nearest value was carried backward or forward, respec-
tively. When more than one consecutive result was miss-
ing, it was considered as a missing value in the analysis. 
Missing data represented 6.7 % of the collected data and 
1.5 % were replaced.
Outcome parameters
The primary outcome parameter in patients with SARI 
was in-hospital mortality within 60 days of admission to 
the ICU. Secondary outcome parameters included death 
in the ICU, ICU and hospital lengths of stay, and organ 
failure as assessed by the SOFA score.
Statistical analyses
Data were analyzed using IBM® SPSS® Statistics soft-
ware, version 22 for Windows, R software, version 
3.2.2 (CRAN project), and MLwiN v.2.28. The Kol-
mogorov–Smirnov test was used to verify the normality 
assumption of continuous variables. Difference testing 
between groups was performed using analysis of vari-
ance (ANOVA), Student’s t test, Mann–Whitney test, Chi 
square test, or Fisher’s exact test, as appropriate.
To identify the independent risk factors for in-hos-
pital death in patients with SARI we used a three-level 
multilevel technique with in-hospital outcome as the 
dependent variable (Table E2). The explanatory variables 
considered in the model were
  • Individual-level factors: age, sex, ethnicity, SAPS  II 
and SOFA scores on admission to the ICU, source 
of admission, comorbidities, mode of acquisition of 
SARI, prior vaccination against pneumococcus or 
influenza, antibiotic administration, adequacy and 
timing (in days) of the antibiotic therapy initiated on 
admission to the ICU, need for mechanical ventila-
tion during the ICU stay, number of days in the hos-
pital prior to ICU admission, and microorganisms 
retrieved at any time during the ICU stay
  • Hospital-level factors: type of hospital, level of care, 
number of staffed ICU beds
  • Country-level factors: for this level, a random inter-
cept model was considered
Data are given as means with standard deviation, medi-
ans, and interquartile ranges (IQR), or numbers and 
percentages (n, %). All statistics were two-tailed and a p 
value less than 0.05 was considered as significant.
Results
Characteristics of study cohort
A total of 206 ICUs from 42 countries contributed to 
the study, mostly located in Western Europe (66.5  %, 
n  =  137) (Table  E3). During the study periods, 5550 
patients were admitted to these units (Fig. 1). A total of 
663 (11.9 %) patients were admitted because of SARI; 364 
in the first and 299 in the second inclusion periods. The 
epidemiology of SARI in the different geographic regions 
is presented in Table E4.
SARI admissions were more likely to be non-surgical 
and to require mechanical ventilation on admission to the 
ICU and at any time during the ICU stay than those who 
were admitted for reasons other than SARI (Table E5).
The characteristics of patients with SARI on admission 
to the ICU are presented in Table  1; these admissions 
were most commonly community-acquired (68.8 %). The 
most common comorbidities in the these patients were 
systemic hypertension (51.3  %) and chronic obstructive 
pulmonary disease (COPD, 31.1 %) (Table E6).
Clinical manifestations, patterns of infection, 
and antimicrobial therapy in SARI patients
The first symptoms occurred at a median of 2 days (IQR 
0–4) before admission to the ICU, most commonly dysp-
nea (92.8  %), cough (75.3  %), and fever (64.7  %). Less 
common symptoms included headache (18.3 %), nausea 
and vomiting (17.4 %), and diarrhea (7.3 %). A history of 
recent foreign travel was reported by 27 patients (4.1 %).
Prior antimicrobial therapy was initiated in 378 
patients (57.0 %) (Table E7) and in 611 patients (96.5 %) 
a new antimicrobial agent was started on admission to 
the ICU, mostly empirically (88.6 %). The initial antimi-
crobial therapy was adequate in 80.6 % of cases. The anti-
microbial regimen was changed in 209 patients (31.5 %) 
because of clinical deterioration (45.2 %), culture results 
(34.8  %), or in the context of de-escalation of therapy 
(19.9  %). Concomitant antimicrobials were used in 130 
patients (19.6) for indications other than treatment of 
SARI.
Specimens were obtained for microbiological examina-
tion in 596 (89.9) patients and were positive for microor-
ganisms in 62.7 % of patients (Table E8). Microbiological 
investigation on admission to the ICU revealed predomi-
nantly Gram-positive (29.6  %) or Gram-negative bacte-
ria (26.2 %) but rarely atypical bacteria (1.0 %); 7.7 % of 
the microorganisms isolated on admission were viruses 
(Table  2). Overall, the most frequently isolated Gram-
positive bacteria was Streptococcus pneumoniae (12.7 %); 
the most frequently isolated Gram-negative microorgan-
ism was Pseudomonas aeruginosa (14.4 %). Viruses were 
isolated in 13.7  % of positive cultures, atypical bacteria 
in 2.9  %, and fungi in 27.6  % of cases. In patients with 
hospital-acquired SARI, Gram-negative microorganisms 
(33.3 vs. 26.5  %, p  =  0.002) and fungi (29.5 vs. 12.8  %, 
p  =  0.001) were more frequently and viral infections 
less frequently (3.9 vs. 9.9 %, p = 0.006) isolated than in 
patients with community-acquired SARI (Fig. 2).
Morbidity and mortality
Organ failure was present on admission to the ICU in 427 
(64.4 %) of the patients with SARI and occurred during 
the entire ICU stay in 495 (74.7 %). Respiratory, cardio-
vascular, and renal failures were the most common organ 
failures (Table  3). The ICU and hospital mortality rates 
were 20.2 and 27.2 %, respectively.
The overall ICU mortality in all patients admitted to 
the contributing centers (n = 5550) was 13.1 % and the 
median ICU stay was 3 (IQR 2–8) days. Patients with 
SARI had higher ICU mortality (20.2 vs. 12.2 %, p < 0.001) 
and longer ICU lengths of stay [5 (2–12) vs. 3 (2–8)] days, 
p < 0.001) than those without SARI (Table E5).
Survivors were younger, more likely to be female, less 
likely to be admitted to the ICU from a hospital ward, 
had lower severity scores on admission to the ICU, and 
had a lower incidence of organ failure during the ICU 
stay (Tables E9, E10) than non-survivors. Survivors were 
more likely to have received pneumococcal or influenza 
vaccines than non-survivors. Arrhythmias, chronic renal 
failure, cancer, asthma, hematologic malignancies, organ 
or bone marrow transplantation, liver disease, immuno-
suppression, or chemotherapy prior to ICU admission 
were more frequent in non-survivors than in survivors 
(Table E7). The most common primary causes of in-hos-
pital death were multiorgan failure (43.6 %) and pneumo-
nia (31.9 %) (Table E11).
In multivariable analysis, older age, greater severity 
scores on admission to the ICU, hematologic malignancy, 
and liver disease were independently associated with an 
increased risk of in-hospital death. Influenza vaccination 
prior to ICU admission, and adequate antibiotic admin-
istration on admission to the ICU were associated with a 
lower risk of in-hospital death (Table E2).
Discussion
The main findings of our study were that (1) SARI was 
a common cause of admission to the ICU and was asso-
ciated with considerable morbidity and high mortal-
ity rates; (2) these infections were predominantly due 
to Gram-positive or Gram-negative bacteria and rarely 
due to atypical bacteria or viruses; and (3) older age, 
greater severity scores, and comorbid conditions were 
independently associated with an increased risk of in-
hospital death in these patients, whereas prior influenza 
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Fig. 1 Flowchart of recruitment to and inclusion in the study. ICU 
intensive care unit, SARI severe acute respiratory infection
vaccination and adequate initial antibiotic administration 
were associated with a lower risk.
Repeated outbreaks of SARI-related epidemics repre-
sent a major healthcare problem [1–4]. Several studies 
have investigated the epidemiology and clinical charac-
teristics of SARI, with a special emphasis on viral etiology 
[13–17] or on the subset of patients admitted to the ICU 
with severe community-acquired pneumonia [17–22]. To 
the best of our knowledge, our study is the first to investi-
gate this issue in a large prospective, multinational cohort 
of critically ill patients with SARI, providing a global view 
of this condition worldwide.
One in ten patients with SARI was treated empiri-
cally without any microbiologic sampling. Increased 
awareness of sepsis should be expected to improve 
compliance with early microbiologic sampling [23]. 
Nevertheless, the low index of suspicion in the absence 
of an ongoing epidemic may explain the relatively low 
rate of investigations aimed at detecting a viral etiol-
ogy. In agreement with previous large epidemiologic 
Table 1 Characteristics of  patients with  severe acute respiratory infections (SARI) on  admission to  the ICU, stratified 
according to the inclusion periods
Missing values n = 2–12 (max 1.8 %), valid percentages are presented after exclusion of missing values
ICU intensive care unit, SAPS simplified acute physiology score, IQR interquartile range, SOFA sequential organ failure assessment score
a India, Pakistan, and Sri Lanka
All patients Inclusion period p value
November 2013 January 2014
N 663 364 299
Age, years, mean ± SD 63.9 ± 16 64.5 ± 15.9 63.1 ± 16.2 0.226
Male, n (%) 386 (58.7) 216 (59.8) 170 (57.2) 0.501
Healthcare worker, n (%) 11 (1.7) 5 (1.4) 6 (2.0) 0.798
Ethnicity, n (%)
 White/Caucasian 441 (67.7) 246 (69.5) 195 (71.3) 0.392
 Asian 49 (7.5) 22 (6.2) 27 (9.1)
 Latin American 46 (6.9) 24 (6.8) 22 (7.4)
 South Asiana 41 (6.2) 23 (6.5) 18 (6.1)
 Arab 34 (5.2) 19 (4.9) 15 (5.1)
 Black 24 (3.6) 15 (4.2) 9 (3.0)
 Others 16 (2.5) 5 (1.4) 11 (3.7)
Source of admission, n (%)
 Community 194 (29.4) 108 (29.9) 36 (22.1) 0.847
 Hospital ward 183 (27.8) 99 (27.4) 64 (39.3)
 Emergency room 165 (25.0) 93 (25.8) 34 (20.9)
 Other hospital 58 (8.8) 33 (9.1) 25 (8.4)
 Long-term facility 24 (3.6) 10 (2.8) 14 (4.7)
 Other ICU 13 (2.0) 2 (0.6) 11 (3.7)
 Step-down/-up 14 (2.1) 10 (2.8) 4 (1.3)
 Others 8 (1.2) 6 (1.7) 2 (0.7)
Severity scores
 SAPS II, mean ± SD 50.4 ± 19.0 49.3 ± 18.2 51.7 ± 19.8 0.178
 SOFA score, median (IQR) 5 (2–9) 5 (2–9) 5 (2–9) 0.727
Mode of acquisition, n (%)
 Community-acquired 452 (68.2) 246 (68.3) 206 (69.4) 0.059
 Healthcare-related 76 (11.5) 37 (10.3) 39 (13.1)
 Nosocomial-acquired 129 (19.5) 77 (21.4) 39 (17.5)
Mechanical ventilation on admission to the ICU
 Invasive 385 (58.1) 208 (57.1) 177 (59.2) 0.594
 Non-invasive 46 (6.9) 28 (7.7) 18 (6.0) 0.399
 Influenza vaccine, n (%) 67 (10.2) 43 (11.9) 24 (8.1) 0.751
 Pneumococcal vaccine, n (%) 49 (7.4) 31 (8.6) 18 (6.0) 0.692
studies in ICU patients with infections [24–26], patho-
genic microorganisms were identified in only 62.7 % of 
patients. Lack of testing for all possible microorganisms 
during microbiological investigations, the relatively 
high rates of prior antibiotic administration with pos-
sible interference with culture results, and inappropri-
ate sampling techniques may hinder microorganism 
identification.
Table 2 Isolated microorganisms (out of 416 patients with positive results)
CMV cytomegalovirus, HSV herpes simplex virus
a Microorganisms isolated both on admission to the ICU and during the ICU stay are counted once
On admission to the ICU After admission Any time in the ICUa
Gram-positive, n (%) 123 (29.6) 123 (29.6) 205 (49.3)
Streptococcus pneumoniae 41 (9.9) 23 (5.5) 53 (12.7)
Staphylococcus aureus sensitive to methicillin 23 (5.5) 27 (6.5) 42 (10.1)
Staph. coag. neg. sensitive to methicillin 15 (3.6) 34 (8.2) 45 (10.8)
S. aureus resistant to methicillin 14 (3.4) 13 (3.1) 26 (6.3)
Staph. coag. neg. resistant to methicillin 7 (1.7) 14 (3.4) 20 (4.8)
Streptococcus A, B, C, G group 7 (1.7) 5 (1.2) 12 (2.9)
Streptococcus, others 14 (3.3) 26 (6.3) 36 (8.6)
Other Gram-positive 10 (2.4) 16 (3.8) 26 (6.3)
Gram-negative, n (%) 109 (26.2) 127 (30.5) 201 (48.3)
Pseudomonas aeruginosa 29 (7.0) 40 (9.6) 60 (14.4)
Klebsiella species 27 (6.5) 36 (8.7) 57 (13.7)
Escherichia coli 23 (5.5) 26 (6.3) 43 (10.3)
Acinetobacter species 15 (3.6) 25 (6.0) 34 (8.2)
Enterobacter species 10 (2.4) 11 (2.6) 21 (5.0)
Proteus species 5 (1.2) 7 (1.7) 10 (2.4)
Citrobacter species 5 (1.2) 2 (0.5) 6 (1.4)
Serratia species 1 (0.2) 5 (1.2) 6 (1.4)
Stenotrophomonas maltophilia 3 (0.7) 5 (1.2) 7 (1.7)
Haemophilus species 7 (1.7) 11 (2.6) 18 (4.3)
Other Gram-negative 4 (1.0 7 (1.7) 11 (2.6)
Anaerobic, n (%) 4 (1.0) 3 (0.7) 7 (1.7)
Clostridium species 2 (0.5) 3 (0.7) 5 (1.2)
Bacteroides 1 (0.2) 0 (0.0) 1 (0.2)
Anaerobe, others 1 (0.2) 0 (0.0) 1 (0.2)
Atypical bacteria, (%) 4 (1.0) 8 (1.9) 12 (2.9)
Mycobacteria 1 (0.2) 1 (0.2) 2 (0.5)
Chlamydia species 0 (0.0) 3 (0.7) 3 (0.7)
Mycoplasma 0 (0.0) 4 (1.0) 4 (1.0)
Legionella pneumophila 3 (0.7) 2 (0.5) 5 (1.2)
Fungi, n (%) 45 (10.8) 83 (20.0) 115 (27.6)
Candida albicans 36 (8.7) 61 (14.7) 87 (20.9)
Candida non-albicans 7 (1.7) 22 (5.3) 28 (6.7)
Aspergillus species 3 (0.7) 7 (1.7) 9 (2.2)
Other 2 (0.5) 9 (2.2) 11 (2.6)
Viruses, n (%) 32 (7.7) 27 (6.5) 57 (13.7)
 Influenza A 23 (5.5) 16 (3.8) 38 (9.1)
 Influenza B 3 (0.7) 0 (0.0) 3 (0.7)
 HSV I or II 0 (0.0)   1 (0.2) 1 (0.2)
 CMV 2 (0.5) 5 (1.2) 6 (1.4)
 Other 5 (1.2) 6 (1.4) 11 (2.6)
Parasites, n (%) 2 (0.5) 3 (0.7) 5 (1.2)
Despite the relatively small number of microbiological 
investigations performed, antimicrobial agents were used 
generously in our cohort. Interestingly, antiviral and anti-
fungal agents were initiated without microbiological evi-
dence of these microorganisms in 6.9 and 4.0 % of cases, 
respectively. The relatively high incidence of comorbid 
conditions in our cohort, especially those related to 
immunosuppression, and the high predominance of life-
threatening organ failure in these patients may explain 
the high use of antimicrobial agents.
The most commonly identified microorganisms were 
Gram-positive and Gram-negative bacteria. The reported 
microorganisms may have included, however, some non-
pathogenic organisms that are not responsible for SARI. 
Interestingly, atypical microorganisms were less frequently 
identified. This observation raises questions regarding the 
frequent empirical use of macrolides in these patients. 
However, macrolides have been reported to have addi-
tional benefits in patients with community-acquired pneu-
monia, irrespective of their antimicrobial effects [27]. 
Moreover, diagnosis of infections with atypical bacteria is 
a considerable challenge, such that the occurrence of these 
infections may be underestimated [28].
Community-acquired infections were common in our 
cohort, explaining the frequent occurrence of infections 
with S.  pneumoniae. The patterns of microbiologic iso-
lates in our study may be useful to guide empirical anti-
microbial therapy in patients with ICU-SARI. Although 
fungi were frequently isolated, only a small proportion 
of these patients received antifungal agents. This finding 
supports the common perception that fungal etiologies 
may not be relevant in all critically ill patients with res-
piratory infections [29].
Our data underscore the poor prognosis of critically 
ill patients with SARI. These patients had considerably 
higher mortality rates and longer lengths of stay com-
pared to patients without SARI. The in-hospital mor-
tality rate in our cohort was similar to rates reported in 
patients with severe community-acquired pneumonia in 
previous studies [17, 20, 30]. This can be explained by the 
frequent occurrence of organ failure in these patients.
We identified several risk factors for in-hospital mor-
tality in the current cohort. These patterns may be use-
ful in identifying patients at risk of poor prognosis. In 
agreement with the results of a meta-analysis of 70 large 
observational studies including 21,338 patients with sep-
sis [31], we found that adequate initial antibiotic admin-
istration was protective in terms of low risk of in-hospital 
death. This supports the early rigorous empiric use of 
wide-spectrum antibiotics in these patients, pending the 
results of microbiological investigations. Nonetheless, 
since the definition of appropriate antibiotic adminis-
tration in the current study was based on both positive 
microbiologic isolates and clinical improvement, we can-
not exclude a possible bias in patients who were judged 
only on the basis of clinical improvement.
Interestingly, prior seasonal influenza vaccination was 
independently associated with a favorable in-hospital 
























Fig. 2 Microbiological isolates according to mode of acquisition of 
severe acute respiratory infection (SARI). *p < 0.05
Table 3 Morbidity and  mortality in  patients with  SARI 
(n = 663)
Missing values: 53 and 64 for ICU and hospital mortality, respectively. Valid 
percentages are displayed after exclusion of the missing values
CNS central nervous system, DNR do not resuscitate order, ICU intensive care 
unit, LOS length of stay, WD withdrawal of life-sustaining therapy (vasopressors, 
mechanical ventilation, and renal replacement therapy), WH withholding of 
life-sustaining measures
a Defined as a SOFA score >2 for the corresponding organ
Organ failure on admission to the ICU, n (%)a
 Respiratory 205 (30.9)
 Cardiovascular 217 (32.7)
 Renal 180 (27.1)
 CNS 138 (20.8)
 Hematologic 54 (8.1)
 Hepatic 29 (4.4)
Organ failure at any time in the ICU, n (%)a
 Respiratory 357 (53.8)
 Cardiovascular 295 (44.5)
 Renal 296 (44.6)
 CNS 216 (32.6)
 Hematologic 133 (20.1)
 Hepatic 50 (7.5)
Mortality rates, n (%)
 ICU 123 (20.2)
 In-hospital 163 (27.2)
Length of stay, days, median (IQR)
 ICU 5 (2–12)
 Hospital 12 (7–23)
Limitation of therapy in-hospital, n (%)
 DNR 72 (11.9)
 WH/WD 57 (9.4)
about 28,000 adults are hospitalized for influenza-asso-
ciated critical illness in the USA annually. A recent bias-
adjusted meta-analysis [33] confirmed that influenza 
vaccine was effective in preventing hospitalization from 
influenza and/or pneumonia and all-cause mortality in 
community-dwelling elderly. However, the evidence to 
support risk factors for influenza-related complications 
is still low and adequately powered studies are needed to 
address this issue [34, 35].
The study had several limitations. First, participation 
was voluntary and was concentrated in some countries 
in Western Europe, so that the results in this report may 
not be extrapolated to all ICU patients worldwide. Sec-
ond, regional and seasonal differences may also occur 
and cannot be captured from our data. Third, some of the 
reported microorganisms may have represented respira-
tory colonization rather than infection. Fourth, the defi-
nitions of infection were not based on only the presence 
of microorganisms and we did not differentiate between 
possible and probable clinical infections. Nonetheless, 
defining infection according to the isolation of a patho-
genic microorganism may also be subject to a certain bias 
because of possible interference from prior antibiotic 
administration, availability and the diagnostic perfor-
mance of the serologic tests, and local practice concern-
ing microbiologic investigations. Fifth, our data may not 
be extrapolated to all hospitalized patients with SARI. 
Finally, the study was purely observational and we did 
not apply standard protocols for diagnosis and therapy in 
patients with SARI; however, our aim was to report cur-
rent practice in these patients.
Conclusions
SARI is a common cause of admission to the ICU and has 
associated high morbidity and mortality rates. Our data 
describe the current patterns of infections and therapy of 
this serious healthcare problem. This information may be 
particularly useful in resource allocation and risk stratifi-
cation for clinical and research purposes.
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Appendix: Alphabetical list of participating centers 
by region and country
Europe
Austria: General Hospital, Braunau (J Auer, G Schatzl); 
Krankenhaus Oberwart, Oberwart (K Mach, H Gruber)
Belgium: Ziekenhuis Oost-Limburg, Genk (E Schreurs, 
M Vander Laenen); Universitair Ziekenhuis, Leuven (H 
Ceunen, J Wauters); CHU Saint-Pierre, Brussels (P Des-
champs); Cliniques Universitaires Saint-Luc UCL, Brus-
sels (D Castanares); CHU Brugmann, Brussels (D Debels, 
C Pierrakos); Erasme University Hospital, Brussels (JL 
Vincent, F Taccone (national coordinator))
Czech Republic: University Hospital Motol, Prague (T 
Vymazal)
Croatia: University Hospital Centre Zagreb, Zagreb (I 
Gornik, A Vujiaklija Brajkovic)
Denmark: Holbaek Sygehus, Holbaek (R Medici); Rig-
shopitalet, Copenhagen (J Nielsen); Glostrup Sygehus, 
Glostrup (A Bendtsen, H Siegel)
Finland: Meilahti Hospital, Helsinki (T Suonsyrjä)
France: CHU Nord, Marseille (S Hraech), Hôpital 
Cochin, Paris (J-D Chiche, F Daviaux); CHRU Stras-
bourg-Hôpital de Hautepierre, Strasbourg (M Guillot, V 
Castelain); CHRU Nancy-Hôpital Brabois-Réanimation 
et soins continus chirurgicaux, Vandoeuvre-Les-Nancy 
(R–R Losser), CHRU Nancy-Hôpital Brabois-Réanima-
tion médicale, Vandoeuvre-Les-Nancy (E Novy); (Hôpi-
tal Bichat, Paris (J-F Timsit (national coordinator), L 
Bouadma); Groupe Hospitalier Paris Saint-Joseph, Paris 
(B Misset, F Philippart); Centre Hospitalier Dr Schaf-
fner, Lens (J Mallat); CHU Amiens, Amiens (E Zogheib, 
M Miclo) Hôpital Bicêtre, Le Kremlin-Bicêtre Paris (J-L 
Teboul, N Anguel); CHU Saint-Etienne, Saint-Etienne 
(M Darmon); Hôpital Tenon, Paris (T Pham); CH Mul-
house-Hôpital Emile Muller, Mulhouse (G Barberet); 
Hôpital Victor Dupouy, Argenteuil (G Plantefeve); Hôpi-
tal Edouard Herriot, Hospices Civils de Lyon, Lyon (B 
Floccard)
Georgia: Georgian Critical Care Medicine Institute, 
Tbilissi (Z Kheladze)
Germany: Universitätsklinikum Jena, Jena (K Rein-
hart (national coordinator), Y Sakr, F Bloos); Klinikum 
Weiden, Weiden in der Oberpfalz (A Faltlhauser); Klini-
kum Luedenscheid, Luedenscheid (T Helmes); Univer-
sity Hospital Frankfurt, Frankfurt am (K Zacharowski, 
P Meybohm); Klinikum Saarbrücken, Saarbrücken (K 
Schwarzkopf); Klinikum Nürnberg, Dept of Emergency 
and Critical Care Medicine, Nurenberg (M Christ, M 
Baumgaertel); Klinikum Nürnberg, Nephrologische 
Intensivstation BU13, Nurenberg (S John, J Nentwich); 
Universitätsmedizin-Charité, Berlin (M Deja, A Gold-
mann); Diakoniekrankenhaus Friederikenstift, Han-
nover (A Gottschalk, F Honig); University Medical 
Center Freiburg, Freiburg (B Siepe, U Goebel); Vivantes 
Humboldt-Klinikum, Berlin (J Lehmke, S Behrens); 
Oberschwabenklinik, Krankenhaus St Elisabeth, Raven-
sburg (K Fiedler); Universitätsmedizin Mainz, Mainz 
(I Sagoschen); University Hospital, Tübingen (R Ries-
sen, M Haap); University Hospital, Leipzig (Ph Simon,U 
Kaisers); Vivantes Klinikum Spandau, Berlin (S Behrens, 
M Niesen); Klinikum Augsburg, Augsburg (U Jaschin-
ski); Universitätsklinikum des Saarlandes, Homburg (S 
Hoersch, A Jung); Robert-Bosch-Krankenhaus, Stuttgart 
(S Allgaeuer); Maria Hilf, Mönchengladbach (H Haake); 
Klinik Hennigsdorf der Oberhavel Kliniken, Hennigsdorf 
(A Lange)
Greece: Hippokrateion General Hospital, Athens 
(M Papanikolaou, M Balla); AHEPA University Hospi-
tal, Thessaloniki (M Giannakou, I Soultati); University 
Hospital of Ioannina, Ioannina (G Nikos, V Koulouras); 
Lamia General Hospital, Lamia (G Kyriazopoulos, D 
Gkika); General Hospital O Agios Dimitrios, Thessalon-
iki (G Vlachogianni, K Psaroulis); Hippokratio Hospital, 
Thessaloniki (E Mouloudi, E Massa)
Ireland: St Vincents University Hospital, Dublin (A 
Nichol, E Meany); Limerick University Hospital, Limer-
ick (C Motherway)
Italy: San Gerardo Hospital, Monza (G Bellani); Pin-
etagrande Private Hospital, Castelvolturno (V Pota, V 
Schiavone); University Hospital of Modena, Modena (M 
Girardis); Azienda Ospedaliera Desenzano, Desenzano 
(N Petrucci, R Di Pasquale); Ospedale Sandro Pertini, 
Rome (P Mazzini); IRCCS San Martino-IST, Genova (A 
Molin, G Pellerano); Arispedale Sant’Anna Hospital, Fer-
rara (C Volta, S Spadaro); Azienda Ospedaliero Univer-
sitaria Pisana, Pisa (F Guarracino); Fondazione IRCCS 
Ca’ Granda-Ospedale Maggiore Policlinico, Milan (M 
Savioli); Santa Maria degli Angeli Hospital, Pordenone 
(T Pellis, N Chinellato); Ospedale Ceccarini, Riccione (A 
Gatta, F Cecchini); Policlinico P Giaccone, Palermo (SM 
Raineri, A Cortegiani)
Lithuania: Vilnius University Hospital Santariskiu Clin-
ics, Vilnius (G Kekstas, V Karosas)
Macedonia: Special Hospital for surgery Fillip II, Skopje 
(T Anguseva, Z Mitrev)
Netherlands: Tjongerschans, Heerenveen (O Beck, N 
Cimic); Atrium Medisch Centrum Parkstad, Heerlen (G 
Janssen, L Bormans); Medical Center Leeuwarden, Leeu-
warden (M Kuiper, K Koopmans); Spaarneziekenhuis, 
Hoofddorp (S Den Boer, M de Groot); Medical Centre 
Haaglanden, The Hague, P Dennesen); Reinier de Graaf 
Ziekenhuis, Delft (J van den Bosch); Slotervaartzieken-
huis, Amsterdam (G Kluge)
Poland: Child Jesus Clinical Hospital of the Medical 
University of Warsaw, Warsaw (M Mikaszewska-Sokole-
wicz, T Lazowski); Szpital Praski, Warsaw (M Chrus-
cikowski); Wroclaw University Hospital, Wroclaw (J 
Machon, B Adamik); Barlicki Clinical Hospital, Lodz (A 
Wieczorek)
Portugal: Hospital de S José, Lisbon (S Afonso, R Matos 
(national coordinator)); Centro Hospitalar do Médio Tejo, 
Abrantes (N Catorze, A Araujo); Hospital de Santa Maria 
EPE (CHLN), Lisbon (Z Costa, A Pais-de-Lacerda); Cen-
tro Hospitalar Tondela-Viseu, Viseu (I Martins); Hospi-
tal Sao Francisco Xavier—CHLO, Lisbon (R Cardiga, L 
Fernandes); Hospital Pr Doutor Fernando Fonseca EPE, 
Amadora (I Serra, A Martinho)
Romania: Fundeni Clinical Institute, Bucharest (D 
Tomescu, E Scarlatescu); Institute of Pneumology, 
Bucharest (R Stoica, A Macri); Emergency Institute for 
Cardiovascular Diseases Prof Dr CC Iliescu, Bucharest 
(D Filipescu (national coordinator))
Slovenia: General Hospital Izola, Izola (E Rupnik); Uni-
versity Clinic of Respiratory and Allergic Diseases, Gol-
nik (V Tomic, F Sifrer)
Spain: Hospital de Gran Canaria Dr Negrín, Las Pal-
mas de Gran Canaria (J Sole Violan, JM; Ferrer Agüero); 
Complejo Hospitalario de Navarra, UCI B, Pamplona (J 
Izura); Clinica Universidad de Navarra, UCI Adultos, 
Pamplona (P Monedero); Hospital de Torrejón, Tor-
rejón de Ardoz (C Muños de Cabo); Hospital Clínico 
Universitario de Valencia, Cuidados intensivos quirur-
gicos, Valencia (G Aguilar, FJ Belda); Hospital Clínico 
Universitario de Valencia, Cuidados Intensivos, Valen-
cia (J Blanquer, E Nives Carbonell); Hospital Univer-
sitari Bellvitge, L’Hospitalet de Llobregat-Barcelona 
(J-C Lopez-Delgado); Hospital Regional Carlos Haya, 
Málaga (C Aragon); Hospital Quirón Sagrado Corazón, 
Seville (C Ortiz-Leyba); Complejo Hospitalario Univer-
sitario de Ferrol, Ferrol (CJ Fernandez Gonzalez); Hos-
pital Universitario Virgen de la Victoria, Málaga (M-V 
de la Torre-Prados, A Puerto-Morlan); Hospital Uni-
versitario Miguel Servet, Zaragoza (P Araujo Aguilar, JI 
Tomás Marsilla); Hospital de la Santa Creu I Sant Pau, 
Barcelona (P Vera Aratcoz, A Olmo); Mutua Terrassa 
University Hospital, Terrasa (R Ferrer Roca (national 
coordinator)); Hospital General de Vic, Vic-Barcelona 
(RM Catalan); Hospital General Universitario Grego-
rio Marañon, Madrid (P Garcia Olivares); Hospital de 
Mataró, Mataró (A Albis); Clinico San Carlos, Madrid 
(M Alvarez); Hospital General Universitario de Albacete, 
Albacete (V Corcoles Gonzalez, J M Gutierrez Rubio); 
Hospital Clínico Universitario Lozano Blesa, Zaragoza 
(R Montoiro Allue); Hospital Infanta Cristina, Badajoz (J 
Rubio Mateo-Sidron)
UK: Bronglais General Hospital, Aberystwyth (M 
Hobrok); St George’s Hospital, London (M Cecconi 
(national coordinator), N Di Tomasso); Barts Health 
NHS Trust, Whipps Cross Hospital, Leytonstone (A Raj); 
Royal Glamorgan Hospital, Llantrisant (T Szakmany, L 
Srinivasa); Alexandra Hospital, Redditch (S Mathew); 
Craigavon Area Hospital, Portadown (A Ferguson); The 
Great Western Hospital, Swindon (M Blahut-Zugaj, M 
Watters); Western Infirmary, Glasgow (S Henderson, M 
Sim); Wexham Park Hospital, Slough (P Csabi); Antrim 
Area Hospital, Antrim (O O’Neill, C Nutt); West Suffolk 
Hospital, Bury St Edmunds (S Humphreys, K Bhowmick); 
Altnagelvin Hospital, Derry (A Donnelly, S O’Kane); 
Ipswich Hospital NHS Trust, Ipswich (M Garfield); Bar-
net General Hospital, Barnet (R Jha, N Unni); Imperial 
College Healthcare NHS Trust-Charing Cross Hospital, 
London (A Gordon, F Rubulotta); Rotherham General 
Hospital, Rotherham (K Ravi, G Lunch); Chase Farm 
Hospital, Enfield (F Federica); Kent and Canterbury Hos-
pital, Canterbury (D Higgs, G Strandvik); Pilgrim Hos-
pital, Boston (A Jonas); King’s College Hospital, London 
(Ph Hopkins, T Hurst); Queen’s Hospital, Romford (A 
Bellini, O Balogun); St Thomas Hospital, London (N Bar-
rett, M Ostermann); University Hospital of South Man-
chester, Manchester (P Alexander, K McCalman); Guy’s 
Hospital, London (M Ostermann); Luton and Dunsta-
ble Hospital, Luton (G Brescia); John Radcliffe Hospital, 
Oxford (J Strachan, J Meyer); Imperial College Health-
care NHS Trust-St Mary’s Hospital, London (M Stotz), 
Imperial College Healthcare NHS Trust-Hammersmith 
Hospital, London (S Brett).
Middle East
Iran: Nemazee Hospital, Shiraz (F Zand, R Nikandish); 
Masih Daneshvari Hospital (NRITLD), Teheran (S 
Hashemian);
Qatar: Hamad General Hospital, Doha (AS Alsheikhly)
Saudi Arabia: Prince Sultan Military Medical City 
(PSMMC), Riyadh (G Almekhlafi); King Faisal Specialist 
Hospital, Riyadh (A Maghrabi, N Salahuddin); King 
Fahad Hospital, Baha (T Aisa)
Turkey: Atasehir Memorial Hospital, Istanbul (H K Ata-
lan); Erciyes Universitesi Tip Fakultesi, Kayseri (M Sungur);
United Arab Emirates: Sheikh Khalifa Medical City, 
Abu Dhabi (M Hegazi).
North America
USA: Mayo Clinic, Saint Mary’s Hospital, Rochester (P 
Bauer); Memorial Medical Center, Springfield (S Muk-
kera); Santa Barbara Cottage Hospital, Santa Barbara 
(J Fried, M Barger); John H Stroger Hospital of Cook 
County, Chicago (R Gueret).
South America
Argentina: Sanatorio Parque, Rosario (C Gonzalez, C 
Lovesio); Hospital Dr Julio C Perrando, Resistencia (Ch 
Dellera, D Barrios)
Brazil: Hospital Universitario Lauro Wanderley, João 
Pessoa (C Leite Mendes, P Gottardo); Hospital Unimed, 
Vitória (E Caser, C Santos); UDI Hospital, São Luís (A 
Carvalho); Hospital Moinhos de Vento, Porto Alegre (C 
Teixeira)
Chile: Hospital del Trabajador, Santiago (W Samaniego, 
S Whittle)
Colombia: Clinica Universitaria Colombia, Bogota 
(D Molano, A Rojas); Clinica Medellín, Medellin (K 
Guerra)
Ecuador: Hospital Militar, Quito (B Villamagua); Cli-
nica La Merced, Quito (E Salgado-Yepez); Hospital de los 
Valles, Quito (D Morocho, N Remache-Vargas)
Mexico: Instituto Nacional de Cancerologia, Mexico 
(S Ñamendys-Silva); Hospital Civil de Guadalajara Hos-
pital Juan I Menchaca, Guadalajara (D Rodriguez); Insti-
tuto Nacional de Ciencias Médicas y Nutrición Salvador 
Zubirán, Mexico (G Dominguez, G Barraza); Hospital 
Regional Leon ISSSTE, Mexico (E Bermudez-Aceves); 
Hospital de Especialidades Antonio Fraga Mouret-
Centro Medico Nacional La Raza IMSS, Mexico (LA 
Sanchez-Hurtado, JA Baltazar-Torres)
Peru: Hospital Nacional Dos de Mayo, Lima (R Quispe 
Sierra, R Ovalle Olmos); Hospital Regional Honorio Del-
gado, Arequipa (C Chavez)
Venezuela: Hospital Central Dr Miguel Pérez Carreño, 
Caracas (I von Osten).
Oceania
Australia: Canberra Hospital, Canberra (C Van Haren 
(national coordinator)); Townsville Hospital, Douglas (N 
Smalley); Concord Hospital, Concord-West Sydney (M 
Kol, H Wong); St Vincent’s Hospital, Fitzroy-Melbourne 
(R Smith).
East and South‑East Asia
China: Wuhan Central Hospital, Wuhan (L Yu, X Wu); 
The First People’s Hospital, Kunming (L Chao); Qilu 
Hospital of Shandong University, Jinan (Q Zhai, D Wu); 
Tenth People’s Hospital, Tongji University School of 
Medicine, Shanghai (X Zhang, X Jing);
Philippines: Chong Hua Hospital, Cebu (R Bigornia, Y 
Ikeda-Maquiling); The Medical City, Pasig (J Robles, JE 
Palo)
Vietnam: Bachmai Hospital, Hanoi (T Nguyen, C Dao).
South Asia
India: Sanjeevan Hospital, Pune (S Dixit), Sanjay Gandhi 
Postgraduate Institute of Medical Sciences, Lucknow (M 
Gurjar); Care Hospital, Hyderabad (P Reddy); Bombay 
Hospital Institute of Medical Sciences, Mumbai Maha-
rashtra (A Pravin (national coordinator)); Hinduja Hospital, 
Mumbai (S Simran); Apollo Hospitals, Chennai (N Ram-
akrishnan); Manipal Hospital, Bangalore (R Shetty); Breach 
Candy Medical Research Centre, Mumbai (F Udwadia)
Pakistan: Shifa International Hospital, Islamabad (M 
Faraz)
Sri Lanka: Sri Jayewardenepura General Hospital, 
Nugegoda (K Indraratna, J Rajasinhe).
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